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VG: Hello, my name is Victoria Glasson and I
am the editor for Diabetes Therapy. Today we are
speaking to Dr Uazman Alam on the treatment
of painful diabetic neuropathy.
UA: Hi Victoria, thanks for that introduc-
tion. My name is Uazman. I am a Senior Clinical
Lecturer in Diabetes and Endocrinology and
also an Honorary Consultant Physician. I work
at the University of Liverpool and Aintree
University Hospital, and I am also an Editorial
Board member for Diabetes Therapy.
VG: So Uazman, how common is painful
diabetic neuropathy?
UA: Painful diabetic neuropathy is a very
common condition, it’s highly prevalent. If we
think about the number of patients we have with
[type 2] diabetes [in the UK], 3.8 million
[4.7 million for all types of diabetes in the UK] [1],
around a third of these will have painful diabetic
neuropathy. So this was primarily shown by the
large study which was undertaken in the North
West of England byCaroline Abbot which showed
a third of all community-based patients had
painful neuropathic symptoms [2]. However,
with increasing severity, painful neuropathic
symptoms increased and with the severest of
diabetic neuropathy there was certainly around
60% of individuals having painful symptoms [2].
VG: And why do patients get pain in diabetes
even when the clinical examination and tests
such as nerve conduction studies are normal?
UA: So the earliest nerve fibres to be affected
are the small nerve fibres [3]. These are the pain-
generating nerve fibres. Now these are not rou-
tinely picked up on in nerve conduction studies
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.11794179.
Electronic Supplementary Material The online
version of this article (https://doi.org/10.1007/s13300-
020-00784-3) contains supplementary material, which is
available to authorized users.
U. Alam (&)
Department of Eye and Vision Sciences and the Pain
Research Institute, Institute of Ageing and Chronic
Disease, University of Liverpool and Liverpool




Division of Endocrinology, Diabetes and
Gastroenterology, University of Manchester,
Manchester, UK
Diabetes Ther (2020) 11:765–772
https://doi.org/10.1007/s13300-020-00784-3
as nerve conduction studies target the larger
fibres known as the A-beta fibres. In terms of a
clinical examination these can be entirely nor-
mal but somebody can still have painful dia-
betic neuropathy. Essentially, pain is generated
from the small nerve fibres which are not rou-
tinely detected by either [gross routine clinical
examination or nerve conduction studies].
VG: What are the sensory symptoms of
painful diabetic neuropathy?
UA: The symptoms can be broadly broken up
into two categories. One is the negative sensory
symptoms and the other is the positive sensory
symptoms. So when I talk of negative sensory
symptoms this includes the feeling of deadness
and numbness, feeling that a person is wearing
gloves and stockings. Positive symptoms are ones
that tend to trouble the patients certainly a lot
more; these include electric shock-like feelings,
aching, tightness, hypersensitivity to touch,
burning and prickling and all of these can cause a
considerable amount of pain and discomfort [4].
VG: What should we be telling the patient
before we start treatment for painful diabetic
neuropathy?
UA: Certainly counselling is an important part
of the treatment for painful diabetic neuropathy
[5].WhenI meancounselling that is the physician
counsel the patient about what is expected and
how the medication works and what they will
need to do with the medication itself or how the
medication should be taken. We certainly need to
tell the patients that the pain relief is not imme-
diate and anti-neuropathic agents do not work in
the same way as a typical pain killer so the actual
pain relief can take a number of weeks. Complete
pain relief is also unlikely and really what we’re
hoping for is improvement in sleep and mood and
also improvement in the patient’s functioning as
well. So really a good outcome is 50% pain relief
[5]. The other important aspect is that patients
should be aware that with most of the medica-
tions, this is particularly true of gabapentin, pre-
gabalin and amitriptyline, that dose increases are
generally required to obtain reasonable pain
relief, so there needs to be an adequate dose
titration.
VG: And what is the role of glycaemic con-
trol in the treatment of painful diabetic
neuropathy?
UA: We should always aim to improve gly-
caemic control and cardiovascular risk covari-
ates; however, there’s no clear [definitive]
evidence to suggest that improving glycemic
control in a person with painful diabetic neu-
ropathy will improve the painful symptoms.
However, saying that, we do need to ensure that
the progression of neuropathy is halted or slo-
wed down, so really treating their glycaemic
control and other cardiovascular covariates
[hyperlipidaemia, hypertriglycaeridemia,
hypertension, BMI, etc.] is really quite impor-
tant. Now, on the other side of glycaemic con-
trol is something which was previously known
as insulin neuritis or what we should call is
treatment-induced neuropathy. This is when
there is a rapid improvement in glycaemic
control. Now, this can rarely cause pain and
there’s been a number of mechanisms which
have been proposed. The one which is by
Solomon Tesfaye [Sheffield, UK] [6] that sug-
gests there may be A–V [arteriovenous] shunt-
ing in the peripheral nerve. But also a
retrospective skin biopsy by Roy Freeman’s
group [Harvard, Boston] has shown that the
majority of people with treatment-induced
neuropathy had underlying diabetic retinopa-
thy [7]. And it’s possible that [underlying]
angiopathy may promote this event so we do
have to keep it in consideration that overly
rapid improvement in glycaemic control, par-
ticularly over a short period of time, can induce
neuropathic symptoms.
VG: Which medications are used in the
treatment of painful diabetic neuropathy?
UA: So the typical medications which tend to
be used and which are categorised as really
being either first- or second-line are anticon-
vulsants and antidepressants. Within the anti-
convulsant class, we have pregabalin and
gabapentin and within the antidepressant class,
we have duloxetine and the tricyclic antide-
pressant i.e. amitriptyline, although other tri-
cyclic antidepressants have also been used.
VG: What are the differences in the inter-
national treatment guidelines for painful dia-
betic neuropathy?
UA: The international guidelines tend to
agree that pregabalin, gabapentin and dulox-
etine and also tricyclics are either first- or
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second-line in the treatment regime [5]. After
this, there is some real divergence in what the
recommendations are. But if we think about
those four medications [classes], these are the
ones that tend to be used as either first- or sec-
ond-line. Now, one difference in the American
Association of Neurology 2011 guidelines [8]
recommended that pregabalin as first-line.
Now, this is largely due to a technical aspect of
the duloxetine studies in which some of them
have a greater than 20% dropout and thus the
level of evidence was not considered quite as
strong [8]. The newer American Academy of
Neurology guidelines are due and we’ll see what
their recommendations are.
VG: What are the differences in efficacy
between gabapentin and tricyclic
antidepressants?
UA: A study has looked at the differences
between these two drugs but there’s really no
significant differences [in efficacy] found [9]. A
meta-analysis of head-to-head trials comparing
the results of gabapentin with two tricyclics did
not show any difference and we know that
pregabalin is similar efficacy to gabapentin in
the most part, so there’s no real difference so far
that has been identified [9]. However, there is a
study which is underway which is called
OPTION-DM this is still underway and this is
looking at combination therapy and treatment
pathways with pregabalin, duloxetine and
amitriptyline and certainly, this will shed more
light on this question [10].
VG: And which medications in the drug class
anticonvulsants are used in the treatment of
diabetic retinopathy?
UA: So the two commonest anticonvulsants
used and the ones with the greatest amount of
evidence is gabapentin and pregabalin. So
gabapentin has an effect. It’s a GABAergic drug
that actually binds to the alpha 2 delta subunit
of voltage-gated calcium channels and it’s
thought to cause an inhibition through this
pathway [11]. Pregabalin has a similar effect and
also binds to the alpha 2 delta ligand [11]. The
other two medications which were previously
used in the anticonvulsant class were carba-
mazepine and phenytoin; however, they’ve
really fallen out of favour now and they’re
rarely used. Carbamazepine tends only to be
used in trigeminal neuralgia. The other anti-
convulsant which has found some favour,
although the level of evidence is not so great, is
sodium valproate and there was a recent
Cochrane review [for neuropathic pain and
fibromyalgia] which suggests that sodium val-
proate did not have any specific advantages
over placebo [12].
VG: Which medications in the class of tri-
cyclic antidepressants are used in the treatment
of diabetic neuropathy?
UA: So the tricyclic antidepressant that’s
most commonly used is amitriptyline and one
of the reasons for this is the trade-off with side
effects that you get with the tricyclic antide-
pressants and the actual efficacy itself. In terms
of the tricyclic antidepressant that has the
lowest number needed to treat for benefit, this
is actually imipramine [13]. [However, the
quality of evidence for imipramine in neuro-
pathic pain is considered poor [14].] However,
imipramine does cause greater side effects than
amitriptyline, so we tend to find that
amitriptyline is more commonly used. Now
amitriptyline generally requires a dose titration;
patients are initiated on lower doses and sub-
sequently a dose titration required to gain
maximal efficacy. Overall, studies of tricyclics in
diabetic neuropathy are small and are likely to
have bias but the decades of use in painful dia-
betic neuropathy means that tricyclics have a
robust standing within the international
guidelines [15]. Interestingly, tricyclics may
have some modulatory effects on the opioid
receptor [16] but one thing we have to consider
is their use is generally cautioned in people with
cardiovascular disease and elderly people, and
tricyclics need to be avoided in people with a
prolonged QT or underlying cardiac
arrhythmias.
VG: Which medications in the class of
selective serotonin–norepinephrine inhibitors
(SNRIs) are used in the treatment of painful
diabetic neuropathy?
UA: The two medications commonly used
within this class are duloxetine and venlafax-
ine. Duloxetine is certainly more commonly
used and has more robust evidence, and
duloxetine is the only one which actually has a
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label for the use in painful diabetic neuropathy
[15]. Other SNRIs are rarely used.
VG: And which medications in the class of
serotonin reuptake inhibitor (SSRIs) are used in
the treatment of painful diabetic neuropathy?
UA: Although studies have been done in this
class, the evidence is not particularly great.
However, we are aware that for people who have
a low mood or are depressed and have painful
neuropathic symptoms, if we can improve their
depressive symptoms then certainly they will
have an improvement in their painful neu-
ropathy symptoms. But these don’t really form
a part of any international guidance and they’re
not routinely used. The two SSRIs which are
used within clinical practice and have been
looked at in painful neuropathy are paroxetine
and citalopram, but I wouldn’t recommend
their use either as first-, second- or even third-
line.
VG: So between pregabalin, gabapentin and
duloxetine is any drug superior?
UA: So there’s not a great deal of data on this;
however, I must refer back to the COMBO-DN
study [17]. So this was a study looking at com-
bination therapy in terms of a combination of
pregabalin and duloxetine vs high-dose
monotherapy. But in the first instance, there
was a run-in phase where people were either put
on duloxetine or pregabalin [at standard doses];
duloxetine was at 60 mg per day and pregabalin
was a total dose of 300 mg per day. And over the
first 8 weeks, duloxetine had lower pain scores.
Now I do emphasise that this was a secondary
endpoint of the study but if we’re thinking
about head-to-head studies really this is the one
probably with the most robust data where it did
show that duloxetine was superior to
pregabalin.
VG: Can non-steroidal anti-inflammatory
drugs (NSAIDs) be used for painful diabetic
neuropathy?
UA: NSAIDs is relatively ineffective for
chronic painful diabetic neuropathy, so they do
not form a part of the treatment guidelines.
VG: And what about opioids? Is morphine
helpful?
UA: Well, we have to think about opioid
class within the treatment of painful diabetic
neuropathy as two separate areas. The first one
is what I call ‘‘opioid plus’’ medication; when I
mean opioid plus these are medications that
have an opioid effect plus an SNRI effect as well.
Now there’s two of these medications which
can be very helpful: tramadol, which is a weak
opioid and has a greater SNRI effect can cer-
tainly be used for breakthrough pain and I do
tend to use this personally myself for people
with breakthrough pain. Now there is a slight
caution in people who are already on dulox-
etine as it can lower the seizure threshold [and
serotonin syndrome] and there is a caution with
the use of both of these in tandem [concur-
rently]. The other opioid of the opioid plus
category, as I call it, is tapentadol, which is a
strong opioid but has a weaker SNRI effect. Now
both of these can be relatively effective in
treating painful neuropathic symptoms. Mor-
phine itself is of little benefit; the standard
opioid medication does not have a great effect
with painful diabetic neuropathy. There have
been some studies of oxycodone but again it
certainly doesn’t form a part of the first- or
second-line therapy that we should be using as
third-line therapy is generally reserved as tra-
madol in some of the international guidelines.
VG: Are there any topical treatments that are
used in the treatment of diabetic neuropathy,
and which are the ones you use in clinical
practice?
UA: So yes there are a number of topical
treatments. So if we think about the topical
treatments that I use in my own clinical prac-
tice, this includes a lidocaine patch, a 5% patch,
and a glyceryl trinitrate (GTN) patch. Now there
is some data that suggests that these can be
helpful and I tend to use this in tandem with
using the 5% lidocaine patch during the day
and the GTN patch at night. The initial studies
were actually done with isosorbide mononitrate
spray which was spayed on the feet but then
subsequently Gerry Rayman showed that GTN
was also effective in their study published in
2003 [18]. The other topical therapy which can
be used in painful diabetic neuropathy is cap-
saicin cream. Now capsaicin cream needs to be
applied multiple times a day and it can actually
induce a burning feeling when it’s applied. It
has an effect via a TRPV1 receptor, also known
as the chilli receptor, but that sort of limits its
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use due to the number of times daily that the
application is required and some of the side
effects that go with it. There is, however, an 8%
capsaicin patch which can be applied now; this
is applied and then the repeat therapy is
required a number of weeks later. But there’s
not a great deal of data really for painful dia-
betic neuropathy for this patch, but I am aware
that there are some ongoing studies.
VG: And are there any other options for
people who do not respond to oral and topical
therapies?
UA: So for those with intractable pain who
are really refractive to oral and to topical ther-
apy, there is the IV lidocaine infusion. Now, this
has previously been used in a study in 2006
which was published in the Journal of Diabetes
and its Complications and was used in painful
diabetic neuropathy [19]. So the dose is recom-
mended at 5–7.5 mg per kg over a period of 4 h
and then generally the therapy is repeated at a
10-weekly basis. And it’s thought around half of
people with intractable pain will have some
kind of benefit from IV lidocaine and it’s
thought the mechanism can be twofold: one is
to reduce the central sensitisation, and the
other is modulation of sodium channels. But
this, of course, requires treatment in a specialist
setting and usually in a pain clinic with [con-
tinuous] ECG monitoring.
VG: What is the role of transcutaneous
electrical nerve stimulation in the treatment of
diabetic neuropathy?
UA: Transcutaneous electrical nerve stimu-
lation has been used in some small studies;
however, there’s no definitive benefit from this,
although if individuals did wish to try transcu-
taneous electric nerve stimulation it would offer
no harm really as long as they were safe to do so
[not contraindicated].
VG: Is there any role for spinal cord stimu-
lator implants in the treatment of diabetic
neuropathy?
UA: So spinal cord stimulators have been
used for a number of years in a number of
conditions but not so frequently in painful
diabetic neuropathy. There have been studies
which have also been undertaken here in
Liverpool back in the 1990s by Solomon Tesfaye
[20]. But certainly, there’s no definitive efficacy
[demonstrated by a large randomised controlled
trial] with spinal cord stimulators and really any
referrals should be made to a pain specialist
within tertiary centres.
VG: So are there any surgical options for
painful diabetic neuropathy?
UA: A number of studies have looked at
decompression surgery [21]. So this is, for
instance, decompression of the lower limb
nerves and also tarsal tunnel surgery. But really
there is again no clear benefit from any of these
procedures in improving painful diabetic neu-
ropathy. Some of the studies that have been
done have been flawed and it’s certainly not
recommended at the present moment.
VG: Is there any way for you to determine
what medication people with painful diabetic
neuropathy will respond to?
UA: So it’s been suggested that the pain
phenotype may determine what medication
people may respond to. So, for instance, when I
mean pain phenotype, in the paper published
by Bouhassira in Pain 2014 [22], [it] was sug-
gested that paraesthesia phenotype in diabetic
neuropathy may respond to duloxetine. When I
mean paraesthesia, these are individuals who
have significant tingling in the limbs. A parox-
ysmal pain, those with paroxysms with pain
may respond better to high dose pregabalin and
this was published by Holbech in Pain 2015
[23]. And also, again, Bouhassira in Pain 2014
showed that combination therapy may actually
be beneficial for moderate pain in painful dia-
betic neuropathy [22]. Now, when studies of
therapeutics in painful diabetic neuropathy
have been undertaken, they’ve not been strati-
fied based on the underlying comorbidities.
What I mean by this is, for instance, individuals
will have a low mood or be depressed, or may
have significant sleep disturbance. So how
would this affect an individual with painful
diabetic neuropathy starting on a therapy? And
certainly, secondary analysis of randomised
controlled trials [in non-specific pain] suggest
that there’s a case for duloxetine in people who
are depressed [24] and in pain and pregabalin
for people who have sleep disturbance and have
painful diabetic neuropathy [25]. So in my own
clinical practice, if somebody is depressed and
has painful diabetic neuropathy, I will tend to
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try them on duloxetine in the first instance or a
tricyclic if the duloxetine is not an option. And
if there’s a significant sleep disturbance then
certainly I will start them on pregabalin [for
painful diabetic neuropathy].
VG: Can psychological therapies help in
painful diabetic neuropathy?
UA: Certainly psychological therapies can be
used and I certainly often refer some patients
with more retractable pain, who are feeling they
may have a more of a psychological aspect to
the pain, to a psychologist. There’s certainly
pain management programs where people can
be referred into and this is certainly an option
for painful diabetic neuropathy.
VG: And what is the role of physical therapy
in the treatment of painful diabetic
neuropathy?
UA: So physical exercise may be of benefit,
there is some trial data in regards to this [26, 27]
but some degree of mild to moderate exercise,
obviously depending on the patient’s comor-
bidities and the status of their heart, can be
considered. And It may be that they have a
reduction of pain. Anecdotally, I’ve found that
people who tend to be more active with painful
diabetic neuropathy tend to have lower pain
scores, but this is certainly anecdotal from my
own clinical experience.
VG: Are there any novel therapies under
development currently that you think are
important to mention?
UA: The one novel therapy really that prob-
ably warrants mentioning is the Nav1.7 channel
modulators or antagonists. Now, this is based
on Nav1.7 channels which line the dorsal root
ganglion and have a really important role in the
modulation of pain [28]; and certainly, in
painful diabetic neuropathy in a [putative]
subset of individuals there’s thought to be a
gain of function in this channel [29]. However,
this is really a class of medication which is
currently being trialled mainly at phase 1 or 2
trials at present and is something that we need
to just keep an eye on.
[For further review and for further reading,
Dr Alam would suggest a paper which he pub-
lished in Clinical Therapeutics 2018 by the name
of ‘‘Diabetic Peripheral Neuropathy: Epidemiol-
ogy, Diagnosis, and Pharmacotherapy’’ [4]. This
a detailed paper looking at the epidemiology
and has detailed sections on pharmacotherapy.]
You can listen to more podcasts by sub-
scribing to Adis Rapid? podcasts with your
preferred podcast provider, or by visiting the
website.
Please note, [brackets] represent additional
information not mentioned in the podcast that
has been added into the transcript by the author
for transparency.
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